Literature DB >> 11850376

Breast cancer.

Monica Morrow1, William Gradishar.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11850376      PMCID： PMC1122337          DOI： 10.1136/bmj.324.7334.410

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  27 in total

1.  ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.

Authors:  A Howell; C K Osborne; C Morris; A E Wakeling
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

2.  The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.

Authors:  J M Dixon; L Renshaw; C Bellamy; M Stuart; G Hoctin-Boes; W R Miller
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

3.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Authors:  S A Narod; J S Brunet; P Ghadirian; M Robson; K Heimdal; S L Neuhausen; D Stoppa-Lyonnet; C Lerman; B Pasini; P de los Rios; B Weber; H Lynch
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

4.  Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer.

Authors:  A E Giuliano; P I Haigh; M B Brennan; N M Hansen; M C Kelley; W Ye; E C Glass; R R Turner
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

5.  Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy.

Authors:  M H Frost; D J Schaid; T A Sellers; J M Slezak; P G Arnold; J E Woods; P M Petty; J L Johnson; D L Sitta; S K McDonnell; T A Rummans; R B Jenkins; J A Sloan; L C Hartmann
Journal:  JAMA       Date:  2000-07-19       Impact factor: 56.272

6.  Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye.

Authors:  L Tafra; D R Lannin; M S Swanson; K M Verbanac; A N Chua; P C Ng; M S Edwards; B E Halliday; C A Henry; L M Sommers; C M Carman; M R Molin; J E Yurko; R R Perry; R Williams
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

7.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

Authors:  J M Nabholtz; A Buzdar; M Pollak; W Harwin; G Burton; A Mangalik; M Steinberg; A Webster; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

8.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Authors:  J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

9.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Authors:  T R Rebbeck; A M Levin; A Eisen; C Snyder; P Watson; L Cannon-Albright; C Isaacs; O Olopade; J E Garber; A K Godwin; M B Daly; S A Narod; S L Neuhausen; H T Lynch; B L Weber
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

10.  Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Authors:  V R Grann; J S Jacobson; W Whang; D Hershman; D F Heitjan; K H Antman; A I Neugut
Journal:  Cancer J Sci Am       Date:  2000 Jan-Feb
View more
  5 in total

Review 1.  Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Authors:  Kate McKeage; Monique P Curran; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells.

Authors:  Brett Wallden; Mary Emond; Mari E Swift; Mary L Disis; Karen Swisshelm
Journal:  BMC Cancer       Date:  2005-10-28       Impact factor: 4.430

3.  Female white-collar workers remain at higher risk of breast cancer after adjustments for individual risk factors related to reproduction and lifestyle.

Authors:  Cecilia Kullberg; Jenny Selander; Maria Albin; Signe Borgquist; Jonas Manjer; Per Gustavsson
Journal:  Occup Environ Med       Date:  2017-04-29       Impact factor: 4.402

4.  Investigating the risk of breast cancer among women exposed to chemicals: a nested case-control study using improved exposure estimates.

Authors:  Cecilia Videnros; Jenny Selander; Pernilla Wiebert; Maria Albin; Nils Plato; Signe Borgquist; Jonas Manjer; Per Gustavsson
Journal:  Int Arch Occup Environ Health       Date:  2019-10-24       Impact factor: 3.015

5.  Study on association between shear wave elastography parameters and clinicopathological characteristics in breast cancer: A protocol for systematic review.

Authors:  Hong-Hong Xue; Yuan-Yuan Wang
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.